Overview

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Status:
Completed

Trial end date:
2021-04-22

Target enrollment:

Participant gender:

Summary

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide or other prophylactic measures.

Phase:

Phase 2

Details

Lead Sponsor:

Puma Biotechnology, Inc.

Treatments:

Antidiarrheals
Budesonide
Colestipol
Loperamide